Assetmark Inc. Buys 86,798 Shares of Fresenius Medical Care AG & Co. KGaA $FMS

Assetmark Inc. increased its stake in shares of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) by 190.7% during the first quarter, HoldingsChannel reports. The institutional investor owned 132,320 shares of the company’s stock after buying an additional 86,798 shares during the quarter. Assetmark Inc.’s holdings in Fresenius Medical Care AG & Co. KGaA were worth $2,985,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in FMS. Advisors Preferred LLC increased its position in shares of Fresenius Medical Care AG & Co. KGaA by 6.1% in the first quarter. Advisors Preferred LLC now owns 10,226 shares of the company’s stock worth $231,000 after purchasing an additional 589 shares during the period. Sequoia Financial Advisors LLC bought a new position in Fresenius Medical Care AG & Co. KGaA in the first quarter valued at approximately $457,000. DMC Group LLC raised its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 15.3% during the 1st quarter. DMC Group LLC now owns 22,460 shares of the company’s stock worth $507,000 after buying an additional 2,986 shares in the last quarter. Kathmere Capital Management LLC acquired a new stake in shares of Fresenius Medical Care AG & Co. KGaA in the 1st quarter valued at approximately $219,000. Finally, QRG Capital Management Inc. boosted its position in Fresenius Medical Care AG & Co. KGaA by 13.8% in the first quarter. QRG Capital Management Inc. now owns 77,128 shares of the company’s stock valued at $1,740,000 after buying an additional 9,357 shares in the last quarter. Institutional investors own 8.37% of the company’s stock.

Fresenius Medical Care AG & Co. KGaA Stock Down 1.4%

Shares of Fresenius Medical Care AG & Co. KGaA stock opened at $24.34 on Thursday. Fresenius Medical Care AG & Co. KGaA has a one year low of $20.02 and a one year high of $27.64. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.20 and a quick ratio of 0.86. The stock’s 50-day moving average is $22.89 and its 200 day moving average is $22.86. The firm has a market cap of $13.07 billion, a price-to-earnings ratio of 12.81, a PEG ratio of 4.39 and a beta of 0.78.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last issued its earnings results on Tuesday, March 31st. The company reported $1.05 earnings per share for the quarter. Fresenius Medical Care AG & Co. KGaA had a return on equity of 8.90% and a net margin of 4.88%.The business had revenue of $5.34 billion during the quarter. Equities research analysts anticipate that Fresenius Medical Care AG & Co. KGaA will post 2.22 EPS for the current year.

Fresenius Medical Care AG & Co. KGaA Increases Dividend

The business also recently disclosed an annual dividend, which was paid on Monday, June 8th. Stockholders of record on Friday, May 22nd were given a dividend of $0.8716 per share. This is a positive change from Fresenius Medical Care AG & Co. KGaA’s previous annual dividend of $0.79. The ex-dividend date of this dividend was Friday, May 22nd. This represents a dividend yield of 402.0%. Fresenius Medical Care AG & Co. KGaA’s payout ratio is 32.11%.

Analysts Set New Price Targets

A number of brokerages have recently commented on FMS. Wall Street Zen lowered Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Sanford C. Bernstein started coverage on Fresenius Medical Care AG & Co. KGaA in a research note on Thursday, July 16th. They issued a “market perform” rating for the company. Weiss Ratings lowered shares of Fresenius Medical Care AG & Co. KGaA from a “hold (c+)” rating to a “hold (c)” rating in a report on Thursday, May 7th. Jefferies Financial Group raised shares of Fresenius Medical Care AG & Co. KGaA from a “strong sell” rating to a “moderate sell” rating in a report on Friday, May 8th. Finally, Citigroup reaffirmed a “neutral” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Friday, July 17th. Six equities research analysts have rated the stock with a Hold rating and four have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Reduce” and a consensus price target of $28.00.

Fresenius Medical Care AG & Co. KGaA Profile

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.